1. Home
  2. HBIO vs IGC Comparison

HBIO vs IGC Comparison

Compare HBIO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HBIO
  • IGC
  • Stock Information
  • Founded
  • HBIO 1901
  • IGC 2005
  • Country
  • HBIO United States
  • IGC United States
  • Employees
  • HBIO N/A
  • IGC N/A
  • Industry
  • HBIO Biotechnology: Laboratory Analytical Instruments
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • HBIO Industrials
  • IGC Health Care
  • Exchange
  • HBIO Nasdaq
  • IGC Nasdaq
  • Market Cap
  • HBIO 19.6M
  • IGC 20.2M
  • IPO Year
  • HBIO 2000
  • IGC N/A
  • Fundamental
  • Price
  • HBIO $0.45
  • IGC $0.36
  • Analyst Decision
  • HBIO Buy
  • IGC Strong Buy
  • Analyst Count
  • HBIO 2
  • IGC 2
  • Target Price
  • HBIO $3.00
  • IGC $3.88
  • AVG Volume (30 Days)
  • HBIO 1.2M
  • IGC 7.2M
  • Earning Date
  • HBIO 08-11-2025
  • IGC 08-07-2025
  • Dividend Yield
  • HBIO N/A
  • IGC N/A
  • EPS Growth
  • HBIO N/A
  • IGC N/A
  • EPS
  • HBIO N/A
  • IGC N/A
  • Revenue
  • HBIO $91,397,000.00
  • IGC $1,271,000.00
  • Revenue This Year
  • HBIO N/A
  • IGC $15.26
  • Revenue Next Year
  • HBIO $9.75
  • IGC $3.41
  • P/E Ratio
  • HBIO N/A
  • IGC N/A
  • Revenue Growth
  • HBIO N/A
  • IGC N/A
  • 52 Week Low
  • HBIO $0.28
  • IGC $0.25
  • 52 Week High
  • HBIO $3.48
  • IGC $0.50
  • Technical
  • Relative Strength Index (RSI)
  • HBIO 49.68
  • IGC 55.26
  • Support Level
  • HBIO $0.39
  • IGC $0.30
  • Resistance Level
  • HBIO $0.48
  • IGC $0.36
  • Average True Range (ATR)
  • HBIO 0.03
  • IGC 0.03
  • MACD
  • HBIO -0.00
  • IGC 0.00
  • Stochastic Oscillator
  • HBIO 67.67
  • IGC 31.06

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: